Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.

Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.

The anthracyclines, such as doxorubicin (DXR), are potent anti-cancer drugs but they are limited by their clinical toxicity. The mechanisms involved remain poorly understood partly because of the difficulty in determining sub-cellular drug localisation. Using a novel method utilising the fluorescent...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Ashley, N, Poulton, J
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2009

Eitemau Tebyg

Targeting DNA with Anthracyclines: The Importance of the Sugar Moiety
gan: Waldemar Priebe
Cyhoeddwyd: (2000-03-01)

Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling.
gan: Ashley, N, et al.
Cyhoeddwyd: (2009)

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect
gan: Junqi Huang, et al.
Cyhoeddwyd: (2022-02-01)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
gan: Craig Davison, et al.
Cyhoeddwyd: (2021-04-01)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
gan: Alessandra Murabito, et al.
Cyhoeddwyd: (2020-03-01)

Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients
gan: Xiaohang Qiao, et al.
Cyhoeddwyd: (2024-06-01)

Anthracyclines, proteasome activity and multi-drug-resistance
gan: Pajonk Frank, et al.
Cyhoeddwyd: (2005-09-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
gan: V. I. Chernov, et al.
Cyhoeddwyd: (2016-02-01)

Anthracyclines
gan: Alison Cheong, et al.
Cyhoeddwyd: (2018-12-01)

Anthracycline cardiomyopathy
gan: Vasiliy Nefedovich Anokhin, et al.
Cyhoeddwyd: (2011-10-01)

Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances
gan: Ashley, N, et al.
Cyhoeddwyd: (2007)

Creation of anthracycline prodrug
gan: A. N. Tevyashova
Cyhoeddwyd: (2014-12-01)

Cardiotoxicity of Anthracyclines
gan: Daniela Cardinale, et al.
Cyhoeddwyd: (2020-03-01)

Anthracycline Cardiotoxicity
gan: Umberto Campia, MD, MSc, et al.
Cyhoeddwyd: (2020-06-01)

Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance
gan: Matthew J. Young
Cyhoeddwyd: (2017-11-01)

Nuclear transfer to prevent mitochondrial DNA diseases.
gan: Poulton, J, et al.
Cyhoeddwyd: (2006)

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer
gan: Yuhan Wei, et al.
Cyhoeddwyd: (2025-01-01)

Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment
gan: Murat Bardakci, et al.
Cyhoeddwyd: (2024-05-01)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
gan: Jacqueline T. Vuong, et al.
Cyhoeddwyd: (2022-04-01)

Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration.
gan: Isao eIshii, et al.
Cyhoeddwyd: (2012-10-01)

Cardiovascular toxicities after anthracycline and VEGF-targeted therapies in adolescent and young adult cancer survivors
gan: Jeannette R. Wong-Siegel, et al.
Cyhoeddwyd: (2023-07-01)

Preventing transmission of maternally inherited mitochondrial DNA diseases
gan: Poulton, J, et al.
Cyhoeddwyd: (2009)

Preventing transmission of maternally inherited mitochondrial DNA diseases.
gan: Poulton, J, et al.
Cyhoeddwyd: (2009)

Preventing transmission of maternally inherited mitochondrial DNA diseases
gan: Poulton, J, et al.
Cyhoeddwyd: (2009)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
gan: Alexandros Briasoulis, et al.
Cyhoeddwyd: (2022-02-01)

DNA damage independent inhibition of NF-κB transcription by anthracyclines
gan: Angelo Ferreira Chora, et al.
Cyhoeddwyd: (2022-12-01)

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
gan: Lucia D’Amico, et al.
Cyhoeddwyd: (2019-01-01)

Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments
gan: Guoxia Zhang, et al.
Cyhoeddwyd: (2022-06-01)

Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
gan: Carmelita Abrahams, et al.
Cyhoeddwyd: (2022-09-01)

Anthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer Treatment.
gan: Chabita Saha, et al.
Cyhoeddwyd: (2016-01-01)

Dexrazoxane in anthracycline cardiotoxicity
gan: Abhijit S Nair
Cyhoeddwyd: (2017-01-01)

Anthracycline-Induced Cardiotoxicity
gan: Radomír Hrdina, et al.
Cyhoeddwyd: (2000-01-01)

A longitudinal evaluation of oxidative stress - mitochondrial dysfunction - ferroptosis genes in anthracycline-induced cardiotoxicity
gan: Ren Qianqian, et al.
Cyhoeddwyd: (2024-07-01)

Molecular assessment of drug-phospholipid interactions consequent to cancer treatment: a study of anthracycline-induced cardiotoxicity
gan: Yara Ahmed, et al.
Cyhoeddwyd: (2023-12-01)

Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity
gan: Carmine Rocca, et al.
Cyhoeddwyd: (2022-02-01)

A screen to identify drug resistant variants to target-directed anti-cancer agents
gan: Azam Mohammad, et al.
Cyhoeddwyd: (2003-01-01)

A careful reassessment of anthracycline use in curable breast cancer
gan: Sara Alsterlind Hurvitz, et al.
Cyhoeddwyd: (2021-10-01)

Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines
gan: Vivian I. Franco, et al.
Cyhoeddwyd: (2011-01-01)

Anthracyclines in the treatment of early breast cancer friend or foe?
gan: Ana Tecic Vuger, et al.
Cyhoeddwyd: (2022-10-01)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
gan: Neha Bansal, et al.
Cyhoeddwyd: (2019-12-01)